Serious adverse events 17 weeks · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in serious adverse events 17 weeks compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Asthma‐related quality of life (MCID) · adults with asthma well controlled on LABA and ICS
1 finding from 1 review
Exacerbation: hospital 17 weeks · adults with asthma well controlled on LABA and ICS
1 finding from 1 review
Adverse events (all) · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in adverse events (all) compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Withdrawal (all‐cause) · adults with asthma well controlled on LABA and ICS
Stopping LABA probably leads to higher withdrawal (all) compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · adults with asthma not well controlled on ICS
1 finding from 1 review
All‐cause serious adverse events 24 weeks · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in all‐cause serious adverse events 24 weeks compared with ICS alone (low certainty).
1 finding from 1 review
Hospital admission (exacerbation) · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in exacerbations requiring hospital admission 24 weeks compared with ICS alone (moderate certainty).
1 finding from 1 review
Change in baseline trough FEV1 · adults with asthma not well controlled on ICS
1 finding from 1 review
Asthma control · adults with asthma not well controlled on ICS
1 finding from 1 review
Any adverse events 24 weeks · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in any adverse events 24 weeks compared with ICS alone (low certainty).
1 finding from 1 review
Mean exacerbations requiring a course of oral corticosteroids · adults with asthma
ICS + LAMA add‐on showed no clear difference in exacerbations requiring a course of OCSa 14 weeks compared with ICS dose increase (low certainty).
1 finding from 1 review
AQLQ score (Scale 1 to 7, where 1 = severely impaired and 7 = no impairment) · adults with asthma
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
SAEs · adults with asthma
ICS + LAMA add‐on showed no clear difference in SAEs (all cause) compared with ICS dose increase (low certainty).
1 finding from 1 review
Exacerbations needing hospitalisation · adults with asthma
ICS + LAMA add‐on showed no clear difference in exacerbations requiring hospitalisation 14 weeks compared with ICS dose increase (low certainty).
1 finding from 1 review
Exacerbations leading to ED visits · adults with asthma
ICS + LAMA add‐on showed no clear difference in exacerbations requiring ED visit 14 weeks compared with ICS dose increase (low certainty).
1 finding from 1 review
FEV1 · adults with asthma
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Moderate
ACQ score Scale = 0 to 6 (0 = no impairment; 6 = maximum impairment) · adults with asthma
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Exacerbations (OCS) · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in exacerbations (OCS) compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).
1 finding from 1 review
AQLQ total 1 = severely impaired; 7 = not impaired at all 22 weeks · adults with asthma not well controlled on ICS
1 finding from 1 review